◎ Sugi Atlas

Atlas / Drug / Procalcitonin

Procalcitonin

drug
On this page

Also known as CalcitoninproProcalcitonin human

Summary

Procalcitonin (CHEMBL2207138) is a phase-3 clinical-stage protein; indicated across 1 condition including chronic obstructive pulmonary disease.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Protein
  • Indications: 1 condition
  • Clinical trials: 48
  • Chemistry: 3475.9 Da · C153H228N40O47S3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2207138
NameProcalcitonin
TypeProtein
Max phase3
FDA approvedno
PubChem CID71452493
Molecular formulaC153H228N40O47S3
Molecular weight3475.9
InChIKeyCWCXERYKLSEGEZ-KDKHKZEGSA-N

SMILES: CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]8CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)CO)CC(C)C)CC(=O)N)N

IUPAC name: (3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-(carboxymethylcarbamoyl)pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10-(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid

Also known as: Calcitonin, pro, Procalcitonin, Procalcitonin human, procalcitonin, PROCALCITONIN

Patent coverage: 1,777 distinct patent families (2,999 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341

Clinical trials

Total trials: 48.

Phase distribution

PhaseTrials
Not specified45
PHASE32
PHASE41

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01025180PHASE4TERMINATEDStudy of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection
NCT01862185PHASE3COMPLETEDThe Effect of Semi-quantitative Procalcitonin Assay to The Adequacy of Empirical Antibiotics and Mortality in Septic Patients
NCT05955612PHASE3COMPLETEDUse of Procalcitonin, a Blood Test to Guide Antibiotic Therapy for Sepsis in Adults
NCT03704766Not specifiedRECRUITINGAlpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
NCT06253325Not specifiedRECRUITINGEarly Detection of At-risk Septic Patients
NCT06352944Not specifiedNOT_YET_RECRUITINGProcalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children
NCT00498121Not specifiedTERMINATEDThe Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)
NCT00726167Not specifiedCOMPLETEDSerum Procalcitonin Study in the Management of Ventilated Patients
NCT00928291Not specifiedCOMPLETEDProcalcitonin Protocol to Shorten the Antibiotic Therapy in Febrile Neutropenia
NCT00987818Not specifiedWITHDRAWNProcalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU
NCT01250574Not specifiedCOMPLETEDNeutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections
NCT01494675Not specifiedCOMPLETEDProcalcitonin as a Tool to Shorten Antibiotic Therapy in the ICU
NCT01498705Not specifiedWITHDRAWNThe Natural History of Procalcitonin in Hemorrhagic Stroke
NCT01847079Not specifiedCOMPLETEDProcalcitonin to Guide Obtaining Bloodcultures in the ICU Intensive Care Infection Score
NCT01977079Not specifiedTERMINATEDProcalcitonin and Threatened Premature Delivery
NCT02104791Not specifiedUNKNOWNEvaluation of the Role of Plasma Procalcitonin in Prediction of Intra-amniotic Infection in Preterm Premature Rupture of Membrane
NCT02130986Not specifiedCOMPLETEDProcalcitonin Antibiotic Consensus Trial (ProACT)
NCT02261610Not specifiedTERMINATEDPulmonary Embolism and PCT. PE-PCT Study
NCT02392689Not specifiedTERMINATEDImprove Management of Heart Failure With Procalcitonin
NCT02899065Not specifiedCOMPLETEDEvaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department
NCT03058718Not specifiedCOMPLETEDProcalcitonin-Guided Antibiotic Therapy in Bronchiectasis
NCT03191071Not specifiedCOMPLETEDAn Algorithm to Decide on Antibiotic Prescription in Lower Respiratory Tract Infection in Primary Care
NCT03223233Not specifiedCOMPLETEDPredicting the Severity of Post-cesarean Wound Infections Using Serum Procalcitonin Levels
NCT03333304Not specifiedCOMPLETEDA Clinical Trial of Procalcitonin-guided Antimicrobial Therapy in Sepsis
NCT03350802Not specifiedCOMPLETEDProcalcitonin Test for Differentiation of the Cause of Pneumonia
NCT03389360Not specifiedCOMPLETEDEvaluation of Procalcitonin (PCT) as a Marker of Infection Post Living Donated Liver Transplant
NCT03433079Not specifiedCOMPLETEDAcute Kidney Injury in Severe Trauma
NCT03440060Not specifiedUNKNOWNProcalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD
NCT03497741Not specifiedCOMPLETEDPredictive Value of Procalcitonin for Bacteremia in the ICU
NCT03506152Not specifiedCOMPLETEDEvaluation of Serum Procalcitonin in Critically Ill Patients With Suspected Sepsis
NCT03560180Not specifiedUNKNOWNEarly Diagnosis of Anastomotic Leakage After Colorectal Surgery: Italian ColoRectal Anastomotic Leakage Study Group.
NCT03683693Not specifiedUNKNOWNProcalcitonin to Guide Antibiotic Stop in Neurocritical Care Patients.
NCT03919266Not specifiedCOMPLETEDCombined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome.
NCT04158804Not specifiedCOMPLETEDPROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT
NCT04203524Not specifiedTERMINATEDProcalcitonin and Antimicrobial Utilization in Critically Ill Cancer Patients with Sepsis
NCT04216277Not specifiedWITHDRAWNThe Procalcitonin Guided Antibiotics in Respiratory Infections in General Practice
NCT04334850Not specifiedCOMPLETEDUse of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia
NCT04573894Not specifiedCOMPLETEDDiagnostic Performance of Plasma Procalcitonin for the Detection of Blood Cultures Contaminations
NCT04634188Not specifiedCOMPLETEDRole and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study
NCT04818866Not specifiedCOMPLETEDInternational Study of Inflammation in COVID-19

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 13

This page pulls from 13 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_ligandmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem